MAPT and Alzheimer disease: Although CSF core biomarkers (Aβ42, t-tau, p-tau) are already indicative in preclinical AD [4], there are still limitations, such as high correlations of p-tau, t-tau and tau PET, which limit the amount of independent diagnostic information available [5], and the need of CSF for detection.